[1] Zheng DD, Duan YZ, Yu R. Trends and risk factors of cardiovascular disease burden in China from 1990 to 2021 and disease burden prediction. Chin Circ J, 2025; 40, 501−7. (In Chinese)
[2] National Health Commission. China health statistics yearbook 2022. Peking Union Medical College Press. 2022. (In Chinese)
[3] Wang W, Liu YN, Liu JM, et al. Mortality and years of life lost of cardiovascular diseases in China, 2005-2020: empirical evidence from national mortality surveillance system. Int J Cardiol, 2021; 340, 105−12. doi:  10.1016/j.ijcard.2021.08.034
[4] GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol, 2024; 23, 973−1003. doi:  10.1016/S1474-4422(24)00369-7
[5] Sun HX, Ge SQ, Jiang B, et al. Incidence of first-ever stroke, stroke events, and early case fatality rate in China: results from a national population-based survey. Neuroepidemiology, 2025; 59, 714−26. doi:  10.1159/000543474
[6] Wang WZ, Jiang B, Sun HX, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation, 2017; 135, 759−71. doi:  10.1161/CIRCULATIONAHA.116.025250
[7] Ren Y, Yang J, Yin P, et al. Urban-rural disparities in mortality due to stroke subtypes in China and its provinces, 2015-2020. Chin Med J, 2025; 138, 1345−54. doi:  10.1097/CM9.0000000000003135
[8] Chinese Center for Disease Control and Prevention. China smoking health hazards report (2020). https://www.chinacdc.cn/jksj/jksj04/202506/P020250616403576918910.pdf. [2026-04-17]. (In Chinese)
[9] Shu YB, Li YL, Wang BW, et al. Burden of cardiovascular diseases attributable to tobacco consumption in the world and China from 1990 to 2021. Chin Circ J, 2025; 40, 38−45. (In Chinese)
[10] Yan YM, Fu HL, Guan LC, et al. Analysis of disease burden of ischemic heart disease attributed to tobacco in China and globally: current status and trends from 1990 to 2021. Chin J Cardiovasc Res, 2025; 23, 366−72. (In Chinese)
[11] National Disease Control and Prevention Administration. Report on Chinese residents’ chronic diseases and nutrition 2020. People's Medical Publishing House. 2022. (In Chinese)
[12] Jia XF, Su C, He YN, et al. Macronutrient intake status and food sources in adult residents from 10 provinces (autonomous regions) of China in 2022-2023. J Hyg Res, 2024; 53, 862−9,879. (In Chinese)
[13] Zhao WH, Li S, Yang Z, et al. China children's nutrition and health status atlas. China Map Publishing House. 2024. (In Chinese)
[14] Huang K, Fang HY, Yu DM, et al. Usual intake of micronutrients and prevalence of inadequate intake among Chinese adults: data from CNHS 2015-2017. Nutrients, 2022; 14, 4714. doi:  10.3390/nu14224714
[15] Liu Z, Man QQ, Li YQ, et al. Estimation of 24-hour urinary sodium and potassium excretion among Chinese adults: a cross-sectional study from the China National Nutrition Survey. Am J Clin Nutr, 2024; 119, 164−73. doi:  10.1016/j.ajcnut.2023.09.005
[16] Chen XC, Zhong FF, Li J. The burden of cardiovascular disease attributable to dietary risk factors in China, 1990-2021. Sci Rep, 2025; 15, 25641. doi:  10.1038/s41598-025-11645-z
[17] Zhong FF, Chen XC, Li J. The burden of type 2 diabetes attributable to dietary risks in China: insights from the global burden of disease study 2021. Public Health, 2024; 237, 122−9. doi:  10.1016/j.puhe.2024.09.026
[18] Cai HY, Talsma EF, Chang ZY, et al. Health outcomes, environmental impacts, and diet costs of adherence to the EAT-Lancet Diet in China in 1997-2015: a health and nutrition survey. Lancet Planet Health, 2024; 8, e1030−42. doi:  10.1016/S2542-5196(24)00285-7
[19] Ng SW, Howard AG, Wang HJ, et al. The physical activity transition among adults in China: 1991-2011. Obes Rev, 2014; 15(S1), 27-36.
[20] Zhang M, Ma YN, Xie XL, et al. Trends in insufficient physical activity among adults in China 2010-18: a population-based study. Int J Behav Nutr Phys Act, 2023; 20, 87. doi:  10.1186/s12966-023-01470-w
[21] Fan X, Cao ZB. Physical activity among Chinese school-aged children: national prevalence estimates from the 2016 Physical Activity and Fitness in China-The Youth Study. J Sport Health Sci, 2017; 6, 388−94. doi:  10.1016/j.jshs.2017.09.006
[22] Guo MM, Koh KT, Wang XZ. Trends of physical activity and recreational screen time among Chinese children and adolescents: a national study from 2017 to 2019. BMC Public Health, 2024; 24, 1305. doi:  10.1186/s12889-024-18822-1
[23] Xin F, Zhu Z, Chen ST, et al. Prevalence and correlates of meeting the muscle-strengthening exercise recommendations among Chinese children and adolescents: results from 2019 Physical Activity and Fitness in China-The Youth Study. J Sport Health Sci, 2022; 11, 358−66. doi:  10.1016/j.jshs.2021.09.010
[24] Song Y, Luo DM, Hu PJ, et al. Trends of prevalence of excellent health status and physical fitness among Chinese Han students aged 13 to 18 years from 1985 to 2014. J Peking Univ (Health Sci), 2020; 52, 317−22. (In Chinese)
[25] Strain T, Brage S, Sharp SJ, et al. Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study. Lancet Glob Health, 2020; 8, e920−30. doi:  10.1016/S2214-109X(20)30211-4
[26] Zhou T, Yuan CX, Shen C, et al. Association between physical activity and incident atherosclerotic cardiovascular disease is modified by predicted cardiovascular risk: the China-PAR project. J Sport Health Sci, 2025; 14, 101031. doi:  10.1016/j.jshs.2025.101031
[27] Zhang C, Chen QZ, Yin FQ, et al. Burden, trends, and predictions of low physical activity-related diseases in China: analysis from the Global Burden of Disease Study, 1990-2021, with projections to 2035. Front Public Health, 2025; 13, 1461554. doi:  10.3389/fpubh.2025.1461554
[28] Ke YL, Shi KX, Bennett DA, et al. Associations of total, domain-specific, and intensity-specific physical activity with all-cause and cause-specific mortality in China: a population-based cohort study. Chin Med J (Engl), 2026; 139, 566−75. doi:  10.1097/CM9.0000000000003485
[29] Lan L, Lang XY, McKee M, et al. Association of sitting time with cardiovascular events among manual and non-manual workers: a prospective cohort study (PURE-China). BMC Public Health, 2025; 25, 750. doi:  10.1186/s12889-025-21948-5
[30] Zhang XF, Wang HJ, Su C, et al. Prevalence and trends of overweight, obesity, and central obesity among adult residents in 10 provinces (autonomous regions) of China in 2000-2023. J Hyg Res, 2024; 53, 874−9. (In Chinese)
[31] Dong YH, Chen L, Liu JY, et al. Epidemiology and prediction of overweight and obesity among children and adolescents aged 7-18 years in China from 1985 to 2019. Chin J Prev Med, 2023; 57, 461−9. (In Chinese)
[32] Global Burden of Disease Study 2023 (GBD 2023). GBD results database. https://vizhub.healthdata.org/gbd-results/. [2026-04-17]. (In Chinese)
[33] Ma GS, Meyer CL, Jackson-Morris A, et al. The return on investment for the prevention and treatment of childhood and adolescent overweight and obesity in China: a modelling study. Lancet Reg Health West Pac, 2024; 43, 100977. doi:  10.3390/nu16173006
[34] Chen L, Zhang Y, Ma T, et al. Prevalence trend of high normal blood pressure and elevated blood pressure in Chinese Han children and adolescents aged 7-17 years from 2010 to 2019. Chin J Prev Med, 2023; 57, 499−507. (In Chinese)
[35] Ma SJ, Yang L, Zhao M, et al. Changing trends in the levels of blood pressure and prevalence of hypertension among Chinese children and adolescents from 1991 to 2015. Chin J Epidemiol, 2020; 41, 178−83. (In Chinese)
[36] Luo YM, Xia F, Yu XX, et al. Long-term trends and regional variations of hypertension incidence in China: a prospective cohort study from the China Health and Nutrition Survey, 1991-2015. BMJ Open, 2021; 11, e042053. doi:  10.1136/bmjopen-2020-042053
[37] Cao X, Wang X, Tian YX, et al. Trends and sociodemographic patterns in hypertension prevalence and treatment in China. Med, 2025; 6, 100808. doi:  10.1016/j.medj.2025.100808
[38] Yi Q, Zha MM, Yang QW, et al. Trends in the prevalence of hypertension according to severity and phenotype in Chinese adults over two decades (1991-2015). J Clin Hypertens, 2021; 23, 1302−15. doi:  10.1111/jch.14306
[39] Wang ZW, Chen Z, Zhang LF, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation, 2018; 137, 2344−56. doi:  10.1161/CIRCULATIONAHA.117.032380
[40] Fu W, Jiao YH, Liu K, et al. Report on the development of China’s basic public health services (2025), Social Sciences Academic Press. 2025. (In Chinese)
[41] Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015. Biomed Environ Sci, 2019; 32, 559−70.
[42] NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020; 582, 73−7. doi:  10.1038/s41586-020-2338-1
[43] Zhao WH, Zhang J, You Y, et al. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Chin J Prev Med, 2005; 39, 306−10. (In Chinese)
[44] Pan L, Yang ZH, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016; 248, 2−9. doi:  10.1016/j.atherosclerosis.2016.02.006
[45] Dai J, Min JQ, Yang YJ. A study on the epidemic characteristics of dyslipidemia in adults of nine provinces of China. Chin J Cardiol, 2018; 46, 114−8. (In Chinese)
[46] National Disease Control and Prevention Administration. Report on Chinese residents’ chronic diseases and nutrition 2015. People's Medical Publishing House. 2015. (In Chinese)
[47] Li SN, Zhang LF, Wang X, et al. Status of dyslipidemia among adults aged 35 years and above in China. Chin Circ J, 2019; 34, 681−7. (In Chinese)
[48] Lu Y, Zhang HB, Lu JP, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China. JAMA Netw Open, 2021; 4, e2127573. doi:  10.1001/jamanetworkopen.2021.27573
[49] Zhang M, Deng Q, Wang LH, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163, 641 adults. Int J Cardiol, 2018; 260, 196−203. doi:  10.1016/j.ijcard.2017.12.069
[50] Opoku S, Gan Y, Fu WN, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and Prevention Project (CNSSPP). BMC Public Health, 2019; 19, 1500. doi:  10.1186/s12889-019-7827-5
[51] Institute for Health Metrics and Evaluation (IHME). Global burden of disease study 2019 (GBD 2019) data resources. http://www.healthdata.org/gbd/2019. [2026-04-17]
[52] Dai HJ, Much AA, Maor E, et al. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes, 2022; 8, 50−60. doi:  10.1093/ehjqcco/qcaa076
[53] Lu JP, Zhang HB, Chen BW, et al. Association and its population heterogeneities between low-density lipoprotein cholesterol and all-cause and cardiovascular mortality: a population-based cohort study. Chin Med J (Engl), 2024; 137, 2075−83. doi:  10.1097/CM9.0000000000003199
[54] Chen L, Chen S, Bai XK, et al. Low-density lipoprotein cholesterol, cardiovascular disease risk, and mortality in China. JAMA Netw Open, 2024; 7, e2422558. doi:  10.1001/jamanetworkopen.2024.22558
[55] Wang LM, Mi SQ, Zhang M, et al. Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults, 2010. Chin J Prev Med, 2012; 46, 687−91. (In Chinese)
[56] Teng HB, Gao Y, Wu CQ, et al. Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: results from China PEACE Million Persons Project. Atherosclerosis, 2022; 350, 58−64. doi:  10.1016/j.atherosclerosis.2022.03.027
[57] Xing YY, Liu J, Hao YC, et al. Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: findings from the Improving Care for Cardiovascular Disease in China (CCC) project. Am Heart J, 2019; 212, 120−8. doi:  10.1016/j.ahj.2019.02.019
[58] Xing YY, Liu J, Liu J, et al. Statin use and low-density lipoprotein cholesterol levels in patients aged 75 years and older with acute coronary syndrome in China. Chin J Cardiol, 2019; 47, 351−9. (In Chinese)
[59] Wang LM, Peng W, Zhao ZP, et al. Prevalence and treatment of diabetes in China, 2013-2018. JAMA, 2021; 326, 2498−506. doi:  10.1001/jama.2021.22208
[60] Wu J, Guo LX. Diabetes atlas of China. People's Medical Publishing House. 2022. (In Chinese)
[61] Wang WH, Qiao JT, Zhang LN, et al. Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: a population-based cross-sectional screening study. Diabetes Obes Metab, 2024; 26, 4251−60. doi:  10.1111/dom.15763
[62] Vazquez Arreola E, Gong QH, Hanson RL, et al. Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study. Lancet Diabetes Endocrinol, 2026; 14, 137−48. doi:  10.1016/S2213-8587(25)00295-5
[63] Wang LM, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance. JAMA Intern Med, 2023; 183, 298−310. doi:  10.1001/jamainternmed.2022.6817
[64] Zhang LX, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet, 2012; 379, 815−22. doi:  10.1016/S0140-6736(12)60033-6
[65] Jia WP, Yu R, Wang LM, et al. Prevalence of chronic kidney disease among Chinese adults with diabetes: a nationwide population-based cross-sectional study. Lancet Reg Health West Pac, 2025; 55, 101463.
[66] He GH, Liu JM, Lin Y, et al. Chronic kidney disease burden from 1990 to 2023 in China: national and provincial insights from the Global Burden of Diseases study 2023. Lancet Reg Health West Pac, 2026; 68, 101776.
[67] Zhang LX, Zhao MH, Zuo L, et al. China kidney disease network (CK-NET) 2017-2018 annual data report. Kidney Int Suppl, 2025; 14, e1−133. doi:  10.1016/j.kisu.2024.12.001
[68] GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet, 2025; 406, 1811−72. doi:  10.1016/S0140-6736(25)01917-8
[69] He DJ, Zhang X, Li CL, et al. Rising prevalence of cardiovascular-kidney-metabolic syndrome in China, 2010-2019: national cross-sectional surveys. JACC, 2025; 86, 213−6. doi:  10.1016/j.jacc.2025.05.030
[70] Wang ZY, Deng X, Yang Z, et al. Association between cardiovascular-kidney-metabolic health metrics and long-term cardiovascular risk: findings from the Chinese Multi-provincial Cohort Study. Chin Med J (Engl), 2025; 138, 2139−47. doi:  10.1097/CM9.0000000000003752
[71] Li M, Xu M, Ding Y, et al. Life's essential 8 cardiovascular health, cardiovascular-kidney-metabolic syndrome stages, and incident cardiovascular events: a nationwide 10-year prospective cohort study in China. Cardiovasc Diabetol, 2025; 24, 197. doi:  10.1186/s12933-025-02735-3
[72] Chen P, Lam MI, Si TL, et al. The prevalence of poor sleep quality in the general population in China: a meta-analysis of epidemiological studies. Eur Arch Psychiatry Clin Neurosci, 2024; 274, 1−14. doi:  10.37766/inplasy2023.4.0055
[73] Lu YK, Tian HD, Shi WT, et al. Associations between mobile phone involvement, BMI levels, and sleep quality among Chinese university students: evidence from a multi-regional large-scale survey. Front Public Health, 2025; 13, 1533613. doi:  10.3389/fpubh.2025.1533613
[74] Diao TY, Liu K, Lyu J, et al. Changes in sleep patterns, genetic susceptibility, and incident cardiovascular disease in China. JAMA Netw Open, 2024; 7, e247974. doi:  10.1001/jamanetworkopen.2024.7974
[75] Zhang Y, Guo JH, Hu XM, et al. Transition of nighttime sleep duration and sleep quality with incident cardiovascular disease among middle-aged and older adults: results from a national cohort study. Arch Public Health, 2025; 83, 91. doi:  10.1186/s13690-025-01577-5
[76] Huang YQ, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019; 6, 211−24. doi:  10.1016/S2215-0366(18)30511-X
[77] Tian W, Yan GC, Xiong SZ, et al. Burden of depressive and anxiety disorders in China and its provinces, 1990-2021: findings from the Global Burden of Disease Study 2021. Br J Psychiatry, 2026; 228, 18−28. doi:  10.1192/bjp.2024.267
[78] Jia ZX, Du X, Du J, et al. Prevalence and factors associated with depressive and anxiety symptoms in a Chinese population with and without cardiovascular diseases. J Affec Disord, 2021; 286, 241−7. doi:  10.1016/j.jad.2021.02.006
[79] Chen R, Liu YY, Yang SC, et al. The prevalence, recognition, and treatment of depression and anxiety symptoms among Chinese cardiovascular outpatients. Sci Rep, 2025; 15, 36798. doi:  10.1038/s41598-025-20683-6
[80] Wang XX, Shi JM, Jiang XY, et al. Association of depressive symptoms with cardiovascular events and plasma BNP: a prospective cohort study of the elderly Chinese population. Arch Gerontol Geriatr, 2024; 123, 105413. doi:  10.1016/j.archger.2024.105413
[81] Yu X, Liu JD, Yin P, et al. Nonlinear relation between cardiac mortality and excess temperature in heatwaves: exposure response in 2.39 million patients. J Am Coll Cardiol, 2025; 85, 1403−16.
[82] Huang Q, Ke LM, Liu LF, et al. Heatwave warnings mitigate long-term cardiovascular diseases risk from heat-related illness: a real-world prospective cohort study. Lancet Reg Health West Pac, 2025; 55, 101468. doi:  10.1016/j.lanwpc.2025.101468
[83] Huang J, He QL, Jiang YX, et al. Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study. Eur Heart J, 2025; 46, 439−50. doi:  10.1093/eurheartj/ehae711
[84] Ji WD, Li L, Cheng YL, et al. Air pollution, lifestyle, and cardiovascular disease risk in northwestern China: a cohort study of over 5.8 million participants. Environ Int, 2025; 199, 109459. doi:  10.1016/j.envint.2025.109459
[85] Li YP, Gao F, Ren CJ, et al. The Netrod™ six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial. Eur Heart J, 2024; 45, 4761−4. doi:  10.1093/eurheartj/ehae703
[86] Jiang XJ, Mahfoud F, Li W, et al. Efficacy and safety of catheter-based radiofrequency renal denervation in Chinese patients with uncontrolled hypertension: the randomized, sham-controlled, multi-center Iberis-HTN trial. Circulation, 2024; 150, 1588−98. doi:  10.1161/CIRCULATIONAHA.124.069215
[87] Wang J, Yin YH, Lu CZ, et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial. eClinicalMedicine, 2024; 72, 102626. doi:  10.1016/j.eclinm.2024.102626
[88] Liu JM, Li Y, Ge JZ, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet, 2024; 404, 245−55. doi:  10.1016/S0140-6736(24)01028-6
[89] Bi YF, Li M, Liu Y, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med, 2025; 392, 1155−67. doi:  10.1056/NEJMoa2412006
[90] He J, Zhao CS, Zhong SS, et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nat Med, 2025; 31, 2054−61. doi:  10.1038/s41591-025-03616-8
[91] Pan WZ, Chen SS, Li W, et al. Early results of multicenter trial of a novel balloon-expandable valve with anchor for aortic regurgitation. JACC Cardiovasc Interv, 2025; 18, 752−64. doi:  10.1016/j.jcin.2024.12.006
[92] Pan XB, Lu FL, Wang YW, et al. Transcatheter tricuspid valve replacement with the novel system: 1-year outcomes from the TRAVEL study. JACC Cardiovasc Interv, 2025; 18, 1276−85.
[93] Wang XQ, Zhou XT, Chen HB, et al. Low driveline infection rates in patients with a novel fully magnetically levitated ventricular assist device. Eur J Cardio-Thorac Surg, 2025; 67, ezaf365. doi:  10.1093/ejcts/ezaf365
[94] Shi GC, Chen SY, Shentu J, et al. Partnership model of regionalized care for congenital heart disease in resource-limited settings: results from the ASSIST project. Circulation, 2025; 152, 113−25. doi:  10.1161/CIRCULATIONAHA.125.074298
[95] He QY, Dou Z, Su ZB, et al. Inpatient costs of congenital heart surgery in China: results from the National Centre for Cardiovascular Diseases. Lancet Reg Health West Pac, 2023; 31, 100623.
[96] Chen L, Hu YX, Saguner AM, et al. Natural history and clinical outcomes of patients with DSG2/DSC2 variant-related arrhythmogenic right ventricular cardiomyopathy. Circulation, 2025; 151, 1213−30. doi:  10.1161/CIRCULATIONAHA.124.072226
[97] Zhang Y, Liu MH, Li PJ, et al. The burden and management competency of cardiomyopathies in China: a nationwide survey study. Lancet Reg Health West Pac, 2024; 46, 101062. doi:  10.1016/j.lanwpc.2024.101062
[98] Zhang SS, Ding RJ, Chen SK, et al. Availability and trend of dissemination of cardiac rehabilitation in China: report from the multicenter national registration platform between 2012 and 2021. Front Cardiovasc Med, 2023; 10, 1210068. doi:  10.3389/fcvm.2023.1210068
[99] Yin L, Zhang XY, Cao YD, et al. Methodological exploration for global cardiovascular academic performance evaluation (CAPE) system. Chin Circ J, 2024; 39, 3−16. (In Chinese)
[100] National Health Commission. China health statistics yearbook 2025. Peking Union Medical College Press. 2025. (In Chinese)
[101] National Center for Cardiovascular Diseases. Report on cardiovascular health and diseases in China 2025: an updated summary. Peking Union Medical College Press. 2026. (In Chinese)